Molecular genetics and genomics progress in urothelial bladder cancer

George J. Netto

Research output: Contribution to journalArticle

Abstract

The clinical management of solid tumor patients has recently undergone a paradigm shift as the result of the accelerated advances in cancer genetics and genomics. Molecular diagnostics is now an integral part of routine clinical management in lung, colon, and breast cancer patients. In a disappointing contrast, molecular biomarkers remain largely excluded from current management algorithms of urologic malignancies. The need for new treatment alternatives and validated prognostic molecular biomarkers that can help clinicians identify patients in need of early aggressive management is pressing. Identifying robust predictive biomarkers that can stratify response to newly introduced targeted therapeutics is another crucially needed development. The following is a brief discussion of some promising candidate biomarkers that may soon become a part of clinical management of bladder cancers.

Original languageEnglish (US)
Pages (from-to)313-320
Number of pages8
JournalSeminars in Diagnostic Pathology
Volume30
Issue number4
DOIs
StatePublished - Nov 1 2013

    Fingerprint

Keywords

  • Biomarkers
  • Molecular bladder
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this